Therapies for hyperglycaemia-induced diabetic complications: From animal models to clinical trials

Nature Reviews Drug Discovery

Volumn 8, Issue 5, 2009, Pages 417-429

  Calcutt, Nigel A ^a   Cooper, Mark E ^b   Kern, Tim S ^c   Schmidt, Ann Marie ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ALISKIREN; ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENFOTIAMINE; BEVACIZUMAB; C PEPTIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ENDOTHELIN RECEPTOR ANTAGONIST; FENOFIBRATE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MURAGLITAZAR; NICOTINAMIDE; OMEGA 3 FATTY ACID; PEGAPTANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PF 4494700; PIOGLITAZONE; PIRFENIDONE; RANIBIZUMAB; ROSIGLITAZONE; RUBOXISTAURIN; THIOCTIC ACID; TRIAMCINOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 65449151412     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2476     Document Type: Review

References (197)

1. Botero, D. & Wolfsdorf, J. I. Diabetes mellitus in children and adolescents. Arch. Med. Res. 36, 281-290 (2005).
2. Turner, R. C. & Holman, R. R. Lessons from UK prospective diabetes study. Diabetes Res. Clin. Pract. 28, S151-S157 (1995).
3. Gabbay, K. H. The sorbitol pathway and the complications of diabetes. N. Engl. J. Med. 288, 831-836 (1973).
4. Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005).
5. Nathan, D. M. et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 348, 2294-2303 (2003).
6. Turner, R., Cull, C. & Holman, R. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 124 136-145 (1996).
7. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
8. Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. & Matthews, D. R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359, 1565-1576 (2008).
9. Feng, L. et al. Chronic vascular inflammation in patients with type 2 diabetes: Endothelial biopsy and RT-PCR analysis. Diabetes Care 28, 379-384 (2005).
10. Crimi, E., Ignarro, L. J. & Napoli, C. Microcirculation and oxidative stress. Free Radic. Res. 41, 1364-1375 (2007).
11. Fadini, G. P. et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler. Thromb. Vasc. Biol. 26, 2140-2146 (2006).
12. Tepper, O. M. et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106, 2781-2786 (2002).
13. Dale, A. C., Vatten, L. J., Nilsen, T. I., Midthjell, K. & Wiseth, R. Secular decline in mortality from coronary heart disease in adults with diabetes mellitus: Cohort study. BMJ 337, 99-102 (2008).
14. Waltman, S., Krupin, T., Hanish, S., Oestrich, C. & Becker, B. Alteration of the blood-retinal barrier in experimental diabetes mellitus. Arch. Ophthalmol. 96, 878-879 (1978).
15. Galman, C. et al. Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol. Am. J. Physiol. Endocrinol. Metab. 293, E737-E742 (2007).
16. Park, L. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Med. 4, 1025-1031 (1998).
17. Renard, C. B. et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest. 114, 659-668 (2004).
18. Johansson, F. et al. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc. Natl Acad. Sci. USA 105, 2082-2087 (2008).
19. Hwang, Y. C. et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J. 18, 1192-1199 (2004).
20. Vikramadithyan, R. K. et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 115, 2434-2443 (2005).
21. Hsueh, W. et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ. Res. 100, 1415-1427 (2007).
22. Clarkson, T. B., Koritnik, D. R., Weingand, K. W. & Miller, L. C. Nonhuman primate models of atherosclerosis: Potential for the study of diabetes mellitus and hyperinsulinemia. Metabolism 34, 51-59 (1985).
23. Gerrity, R. G., Natarajan, R., Nadler, J. L. & Kimsey, T. Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50, 1654-1665 (2001).
24. Johnstone, M. T. et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88, 2510-2516 (1993).
25. Colombo, P. C. et al. Endothelial cell activation in patients with decompensated heart failure. Circulation 111, 58-62 (2005).
26. [No authors listed.] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977-986 (1993).
27. [No authors listed.] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317, 703-713 (1998).
28. Nishikawa, T. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790 (2000).
29. Ishii, H. et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272, 728-731 (1996).
30. Lambeth, J. D. Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropy. Free Radic. Biol. Med. 43, 332-347 (2007).
31. Wautier, M. P. et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280, E685-E694 (2001).
32. Brownlee, M., Cerami, A. & Vlassara, H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315-1321 (1988).
33. Herold, K. et al. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: Inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol. 82, 204-212 (2007).
34. -/- mice. J. Clin. Invest. 118, 183-194 (2008).
35. Soro-Paavonen, A. et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57, 2461-2469 (2008).
36. Suzen, S. & Buyukbingol, E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem. 10, 1329-1352 (2003).
37. Joy, S. V. et al. Ruboxistaurin, a protein kinase C β inhibitor, as an emerging treatment for diabetes microvascular complications. Ann. Pharmacother. 39, 1693-1699 (2005).
38. McGill, J. B. et al. Clinical safety of the selective PKC-β inhibitor, ruboxistaurin. Expert Opin. Drug Saf. 5, 835-845 (2006).
39. Kass, D. A. et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104, 1464-1470 (2001).
40. Zieman, S. J. et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J. Hypertens. 25, 577-583 (2007).
41. Stirban, A. et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29, 2064-2071 (2006).
42. Rong, L. L. et al. Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J. 18, 1812-1817 (2004).
43. Rong, L. L. et al. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J. 18, 1818-1825 (2004).
44. Ludwig, S. & Shen, G. X. Statins for diabetic cardiovascular complications. Curr. Vasc. Pharmacol. 4, 245-251 (2006).
45. Panunti, B. & Fonseca, V. Effects of PPAR gamma agonists on cardiovascular function in obese, nondiabetic patients. Vascul. Pharmacol. 45, 29-35 (2006).
46. Collins, R., Armitage, J., Parish, S., Sleigh, P. & Peto, R. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
47. Kearney, P. M. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with Diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 371, 117-125 (2008).
48. Calkin, A. C. et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler. Thromb. Vasc. Biol. 25, 1903-1909 (2005).
49. Ratner, R. E. et al. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics. Am. Heart J. 156, 1074-1079 (2008).
50. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
51. Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 Diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366, 1279-1289 (2005).
52. Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 Diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366, 1849-1861 (2005).
53. Keech, A. C. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 370, 1687-1697 (2007).
54. Nissen, S. E., Wolski, K. & Topol, E. J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 Diabetes mellitus. JAMA 294, 2581-2586 (2005).
55. Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 Diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
56. Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes. N. Engl. J. Med. 358 2560-2572 (2008).
57. Goh, S.-Y. & Cooper, M. E. Clinical review: The role of advanced glycation end products in progression and complications of Diabetes. J. Clin. Endocrinol. Metabolism 93, 1143-1152 (2008).
58. Chalmers, J. & Cooper, M. E. UKPDS and the legacy effect. N. Engl. J. Med. 359, 1618-1620 (2008).
59. El-Osta, A. et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205, 2409-2417 (2008).
60. Mack, C. P. An epigenetic clue to diabetic vascular disease. Circ. Res. 103, 568-570 (2008).
61. Villeneuve, L. M. et al. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in Diabetes. Proc. Natl Acad. Sci. USA 105 9047-9052 (2008).
62. Gaede, P., Lund-Andersen, H., Parving, H.-H. & Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 Diabetes. N. Engl. J. Med. 358, 580-591 (2008).
63. Gilbertson, D. T. et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J. Am. Soc. Nephrol. 16, 3736-3741 (2005).
64. Mogensen, C. E., Christensen, C. K. & Vittinghus, E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Suppl. 2), 64-78 (1983).
65. [No authors listed.] UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 36, 1021-1029 (1993).
66. Amico, J. A. & Klein, I. Diabetic management in patients with renal failure. Diabetes Care 4, 430-434 (1981).
67. Cooper, M. E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352, 213-219 (1998).
68. Molitch, M. E. et al. Nephropathy in Diabetes. Diabetes Care 27, S79-S83 (2004).
69. Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 Diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
70. Tikellis, C. et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental Diabetes. Diabetes 57, 1018-1025 (2008).
71. Zhang, Z. et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc. Natl Acad. Sci. USA 105, 15896-15901 (2008).
72. Breyer, M. D. et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 16, 27-45 (2005).
73. Gurley, S. B. et al. Impact of genetic background on nephropathy in diabetic mice. Am. J. Physiol. Renal Physiol. 290, F214-F222 (2006).
74. Zheng, S. et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53, 3248-3257 (2004).
75. Mauer, S. M. et al. Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 74, 1143-1155 (1984).
76. Susztak, K., Raff, A. C., Schiffer, M. & Bottinger, E. P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225-233 (2006).
77. Oldfield, M. D. et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. 108 1853-1863 (2001).
78. Wendt, T. M. et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137 (2003).
79. Cooper, M. E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44 1957-1972 (2001).
80. Flyvbjerg, A. et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53, 166-172 (2004).
81. Ziyadeh, F. N. et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA 97, 8015-8020 (2000).
82. Burns, W. C. et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J. Am. Soc. Nephrol. 17, 2484-2494 (2006).
83. Thomas, M. C. et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J. Am. Soc. Nephrol. 16 2976-2984 (2005).
84. Forbes, J. M., Cooper, M. E., Oldfield, M. D. & Thomas, M. C. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14, S254-S258 (2003).
85. Tuttle, K. R. et al. The effect of ruboxistaurin on nephropathy in type 2 Diabetes. Diabetes Care 28, 2686-2690 (2005).
86. Deelman, L. & Sharma, K. Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr. Opin. Nephrol. Hypertens. 18, 85-90 (2009).
87. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 Diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
88. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 Diabetes. N. Engl. J. Med. 345, 851-860 (2001).
89. Bakris, G. L. et al. The future of clinical trials in chronic renal disease: Outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. J. Clin. Pharmacol. 40, 815-825 (2000).
90. MacIsaac, R. J. et al. Nonalbuminuric renal insufficiency in type 2 Diabetes. Diabetes Care 27, 195-200 (2004).
91. Otu, H. H. et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 30, 638-643 (2007).
92. Centers for Disease Control and Prevention. National Diabetes fact sheet: General information and national estimates on Diabetes in the United States (Department of Health and Human Services,Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 2005).
93. Frank, R. N. Diabetic retinopathy. N. Engl. J. Med. 350, 48-58 (2004).
94. Bresnick, G. H., Engerman, R., Davis, M. D., de Venecia, G. & Myers, F. L. Patterns of ischemia in diabetic retinopathy. Trans. Sect. Ophthalmol. Am. Acad. Ophthalmol. Otolaryngol. 81, OP694-OP709 (1976).
95. Roy, M. S. et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch. Ophthalmol. 122, 546-551 (2004).
96. Kempen, J. H. et al. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol. 122, 552-563 (2004).
97. Engerman, R. L. & Kern, T. S. Retinopathy in animal models of Diabetes. Diabetes Metab. Rev. 11, 109-120 (1995).
98. Kern, T. S. in Retinal and Choroidal Angiogenesis (ed. Penn, J. S.) 81-102 (Springer, Dordrecht, 2008).
99. Madan, A. & Penn, J. S. Animal models of oxygeninduced retinopathy. Front. Biosci. 8, d1030-d1043 (2003).
100. Ohno-Matsui, K. et al. Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment. Am. J. Pathol. 160, 711-719 (2002).
101. van Eeden, P. E. et al. Characterisation of a model for retinal neovascularisation. VEGF model characterisation. Adv. Exp. Med. Biol. 572, 163-168 (2006).
102. Ruberte, J. et al. Increased ocular levels of IGF-1 in transgenic mice lead to Diabetes-like eye disease. J. Clin. Invest. 113 1149-1157 (2004).
103. Kern, T. S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95-103 (2007).
104. Barber, A. J. et al. Neural apoptosis in the retina during experimental and human Diabetes. Early onset and effect of insulin. J. Clin. Invest. 102, 783-791 (1998).
105. Scott, T. M., Foote, J., Peat, B. & Galway, G. Vascular and neural changes in the rat optic nerve following induction of Diabetes with streptozotocin. J. Anat. 144, 145-152 (1986).
106. Barber, A. J. et al. The Ins2Akita mouse as a model of early retinal complications in Diabetes. Invest. Ophthalmol. Vis. Sci. 46, 2210-2218 (2005).
107. Engerman, R. L. & Kern, T. S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36, 808-812 (1987).
108. Kern, T. S. & Engerman, R. L. A mouse model of diabetic retinopathy. Arch. Ophthalmol. 114, 986-990 (1996).
109. Engerman, R. L. & Kern, T. S. Experimental galactosemia produces diabetic-like retinopathy. Diabetes 33, 97-100 (1984).
110. Robison, W. G. Jr, Nagata, M., Laver, N., Hohman, T. C. & Kinoshita, J. H. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest. Ophthalmol. Vis. Sci. 30, 2285-2292 (1989).
111. Barile, G. R. et al. The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 46, 2916-2924 (2005).
112. Dorrell, M., Uusitalo-Jarvinen, H., Aguilar, E. & Friedlander, M. Ocular neovascularization: Basic mechanisms and therapeutic advances. Surv. Ophthalmol. 52, S3-S19 (2007).
113. Adamis, A. P. & Berman, A. J. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 30 65-84 (2008).
114. [No authors listed.] Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98, 823-833 (1991).
115. [No authors listed.] Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98, 786-806 (1991).
116. [No authors listed.] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 Diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 (1998).
117. Neubauer, A. S. & Ulbig, M. W. Laser treatment in diabetic retinopathy. Ophthalmologica 221, 95-102 (2007).
118. Moravski, C. J. et al. The renin-angiotensin system influences ocular endothelial cell proliferation in Diabetes: Transgenic and interventional studies. Am. J. Pathol. 162, 151-160 (2003).
119. Chaturvedi, N. et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 Diabetes: Randomised, placebo-controlled trials. Lancet 372, 1394-1402 (2008).
120. Sjolie, A. K. et al. Effect of candesartan on progression and regression of retinopathy in type 2 Diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 372, 1385-1393 (2008).
121. Gillies, M. C., Islam, F. M., Zhu, M., Larsson, J. & Wong, T. Y. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br. J. Ophthalmol. 91 1323-1326 (2007).
122. Kang, S. W., Park, S. C., Cho, H. Y. & Kang, J. H. Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema. Am. J. Opthalmol. 144, 878-885 (2007).
123. [No authors listed.] A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch. Ophthalmol. 108, 1234-1244 (1990).
124. [No authors listed.] Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98, 757-765 (1991).
125. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54, 2188-2197 (2005).
126. The PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: Thirty-month results of the randomized PKC-DMES clinical trial. Arch. Ophthalmol. 125, 318-324 (2007).
127. Aiello, L. P. et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113, 2221-2230 (2006).
128. Davis, M. D. et al. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 50, 1-4 (2009).
129. Starita, C., Patel, M., Katz, B. & Adamis, A. P. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev. Ophthalmol. 39, 122-148 (2007).
130. Iwasaki, T. et al. Three-dimensional optical coherence tomography of proliferative diabetic retinopathy. Br. J. Ophthalmol. 92 713 (2008).
131. Berkowitz, B. A., Roberts, R., Stemmler, A., Luan, H. & Gradianu, M. Impaired apparent ion demand in experimental diabetic retinopathy: correction by lipoic acid. Invest. Ophthalmol. Vis. Sci. 48, 4753-4758 (2007).
132. Trick, G. L., Edwards, P., Desai, U. & Berkowitz, B. A. Early supernormal retinal oxygenation response in patients with Diabetes. Invest. Ophthalmol. Vis. Sci. 47, 1612-1619 (2006).
133. Selvarajah, D. et al. Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes Care 29, 2664-2669 (2006).
134. Wessels, A. M. et al. Microvascular disease in type 1 Diabetes alters brain activation: A functional magnetic resonance imaging study. Diabetes 55, 334-340 (2006).
135. Pirart, J. [Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973 (author's transl.)]. Diabete Metab. 3, 97-107 (1977).
136. Sharma, A. K. & Thomas, P. K. Peripheral nerve structure and function in experimental Diabetes. J. Neurol. Sci. 23, 1-15 (1974).
137. Brussee, V. et al. Distal degenerative sensory neuropathy in a long term type 2 Diabetes rat model. Diabetes 57, 1664-1673 (2008).
138. Kamiya, H., Zhang, W. & Sima, A. A. Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats. Diabetologia 49, 2763-2774 (2006).
139. Bianchi, R. et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl Acad. Sci. USA 101 823-828 (2004).
140. Chen, Y. S., Chung, S. S. & Chung, S. K. Noninvasive monitoring of Diabetes-induced cutaneous nerve fiber loss and hypoalgesia in Thy1-YFP transgenic mice. Diabetes 54, 3112-3118 (2005).
141. Engerman, R. L., Kern, T. S. & Larson, M. E. Nerve conduction and aldose reductase inhibition during 5 years of Diabetes or galactosaemia in dogs. Diabetologia 37, 141-144 (1994).
142. Good, K. L., Maggs, D. J., Hollingsworth, S. R., Scagliotti, R. H. & Nelson, R. W. Corneal sensitivity in dogs with Diabetes mellitus. Am. J. Vet. Res. 64, 7-11 (2003).
143. Walker, D. et al. Nerve pathology in the type 1 diabetic dog: effects of treatment with sulindac. J. Peripher. Nerv. Syst. 6 219-226 (2001).
144. Pare, M. et al. Differential hypertrophy and atrophy among all types of cutaneous innervation in the glabrous skin of the monkey hand during aging and naturally occurring type 2 Diabetes. J. Comp. Neurol. 501, 543-567 (2007).
145. Estrella, J. S. et al. Endoneurial microvascular pathology in feline diabetic neuropathy. Microvasc. Res. 75, 403-410 (2008).
146. Mizisin, A. P. et al. Comparable myelinated nerve pathology in feline and human Diabetes mellitus. Acta Neuropathol. 113, 431-442 (2007).
147. Cameron, N. E., Eaton, S. E., Cotter, M. A. & Tesfaye, S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44, 1973-1988 (2001).
148. Pop-Busui, R., Sima, A. & Stevens, M. Diabetic neuropathy and oxidative stress. Diabetes Metab. Res. Rev. 22, 257-273 (2006).
149. Toth, C., Martinez, J. & Zochodne, D. W. RAGE, Diabetes, and the nervous system. Curr. Mol. Med. 7, 766-776 (2007).
150. Calcutt, N. A., Jolivalt, C. G. & Fernyhough, P. Growth factors as therapeutics for diabetic neuropathy. Curr. Drug Targets 9, 47-59 (2008).
151. Tomlinson, D. R. & Gardiner, N. J. Glucose neurotoxicity. Nature Rev. Neurosci. 9, 36-45 (2008).
152. Mizisin, A. P., Calcutt, N. A., DiStefano, P. S., Acheson, A. & Longo, F. M. Aldose reductase inhibition increases CNTF-like bioactivity and protein in sciatic nerves from galactose-fed and normal rats. Diabetes 46, 647-652 (1997).
153. Suzuki, T., Sekido, H., Kato, N., Nakayama, Y. & Yabe-Nishimura, C. Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: Involvement of the polyol pathway. J. Neurochem. 91, 1430-1438 (2004).
154. Calcutt, N. A., Freshwater, J. D., Hauptmann, N., Taylor, E. M. & Mizisin, A. P. Protection of sensory function in diabetic rats by neotrofin. Eur. J. Pharmacol. 534, 187-193 (2006).
155. Riaz, S., Malcangio, M., Miller, M. & Tomlinson, D. R. A vitamin D(3) derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia 42, 1308-1313 (1999).
156. Kakinoki, B. et al. Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes 55, 616-621 (2006).
157. Goss, J. R. et al. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced Diabetes in the mouse. Diabetes 51, 2227-2232 (2002).
158. Walwyn, W. M. et al. HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy. Exp. Neurol. 198, 260-270 (2006).
159. Kato, N. et al. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes 54, 846-854 (2005).
160. Pradat, P. F. et al. Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. Hum. Gene Ther. 12, 2237-2249 (2001).
161. Chattopadhyay, M. et al. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. 12, 1377-1384 (2005).
162. Price, S. A. et al. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 55, 1847-1854 (2006).
163. Sugimoto, K., Murakawa, Y., Zhang, W., Xu, G. & Sima, A. A. Insulin receptor in rat peripheral nerve: Its localization and alternatively spliced isoforms. Diabetes Metab. Res. Rev. 16, 354-363 (2000).
164. Huang, T. J. et al. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 52, 2129-2136 (2003).
165. Hoybergs, Y. M. & Meert, T. F. The effect of low-dose insulin on mechanical sensitivity and allodynia in type I Diabetes neuropathy. Neurosci. Lett. 417, 149-154 (2007).
166. Brussee, V., Cunningham, F. A. & Zochodne, D. W. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 53 1824-1830 (2004).
167. Pierson, C. R., Zhang, W., Murakawa, Y. & Sima, A. A. Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J. Neuropathol. Exp. Neurol. 62, 260-271 (2003).
168. Cole, G. M. & Frautschy, S. A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp. Gerontol. 42, 10-21 (2007).
169. Li, Z. G., Zhang, W. & Sima, A. A. Alzheimer-like changes in rat models of spontaneous Diabetes. Diabetes 56, 1817-1824 (2007).
170. Burdo, J. R., Chen, Q., Calcutt, N. A. & Schubert, D. The pathological interaction between Diabetes and presymptomatic Alzheimer's disease. Neurobiol. Aging 26 Mar 2008 (doi:10.1016/ j.neurobiolaging.2008.02.010).
171. Jolivalt, C. G. et al. Defective insulin signaling pathway and increased GSK-3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 86, 3265-3274 (2008).
172. Jacobson, A. M. et al. Long-term effect of Diabetes and its treatment on cognitive function. N. Engl. J. Med. 356, 1842-1852 (2007).
173. Kloppenborg, R. P., van den Berg, E., Kappelle, L. J. & Biessels, G. J. Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. Eur. J. Pharmacol. 585, 97-108 (2008).
174. Li, L. & Holscher, C. Common pathological processes in Alzheimer disease and type 2 Diabetes: A review. Brain Res. Rev. 56, 384-402 (2007).
175. Attal, N. et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13, 1153-1169 (2006).
176. Backonja, M. & Glanzman, R. L. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin. Ther. 25, 81-104 (2003).
177. Freynhagen, R., Strojek, K., Griesing, T., Whalen, E. & Balkenohl, M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, doubleblind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115, 254-263 (2005).
178. Raskin, J. et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 6, 346-356 (2005).
179. Ruessmann, H. J. Switching from pathogenetic treatment with α-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J. Diabetes Complications 9 Apr 2008 (doi:10.1016/j.jdiacomp.2008.02.002).
180. Craner, M. J., Klein, J. P., Renganathan, M., Black, J. A. & Waxman, S. G. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann. Neurol. 52, 786-792 (2002).
181. 1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J. Pharmacol. Exp. Ther. 303, 1199-1205 (2002).
182. Jolivalt, C. G., Jiang, Y., Freshwater, J. D., Bartoszyk, G. D. & Calcutt, N. A. Dynorphin A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats. Diabetologia 49, 2775-2785 (2006).
183. Ramos, K. M., Jiang, Y., Svensson, C. I. & Calcutt, N. A. Pathogenesis of spinally mediated hyperalgesia in Diabetes. Diabetes 56, 1569-1576 (2007).
184. Bird, S. J., Brown, M. J., Spino, C., Watling, S. & Foyt, H. L. Value of repeated measures of nerve conduction and quantitative sensory testing in a diabetic neuropathy trial. Muscle Nerve 34, 214-224 (2006).
185. Bril, V. & Buchanan, R. A. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29, 68-72 (2006).
186. Greene, D. A., Arezzo, J. C. & Brown, M. B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 53, 580-591 (1999).
187. Lauria, G. et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur. J. Neurol. 12, 747-758 (2005).
188. Lauria, G. & Devigili, G. Skin biopsy as a diagnostic tool in peripheral neuropathy. Nature Clin. Pract. Neurol. 3, 546-557 (2007).
189. Smith, A. G., Ramachandran, P., Tripp, S. & Singleton, J. R. Epidermal nerve innervation in impaired glucose tolerance and Diabetes-associated neuropathy. Neurology 57, 1701-1704 (2001).
190. Pittenger, G. L. et al. Intraepidermal nerve fibers are indicators
191. Quattrini, C. et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 56, 2148-2154 (2007).
192. Mehra, S. et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 Diabetes. Diabetes Care 30, 2608-2612 (2007).
193. Effect of intensive therapy on the microvascular complications of type 1 Diabetes mellitus. JAMA 287, 2563-2569 (2002).
194. Ludvigson, M. A. & Sorenson, R. L. Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes 29, 450-459 (1980).
195. Ludvigson, M. A. & Sorenson, R. L. Immunohistochemical localization of aldose reductase. I. Enzyme purification and antibody preparation - localization in peripheral nerve, artery, and testis. Diabetes 29, 438-449 (1980).
196. Pachydaki, S. I. et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res. 82, 807-815 (2006).
197. Toth, C. et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 57, 1002-1017 (2008).